Mesotherapy products — injectable and topical formulations for skin rejuvenation, hair growth, and body contouring — occupy a specific niche in Asia’s beauty and aesthetic medicine market. Spain has several credible producers in this space. Getting from Spanish production to Asian clinic and pharmacy distribution requires understanding a market that is structurally different from Europe.
The Asia aesthetic medicine market in 2026
Asia’s medical aesthetics market exceeded USD 18 billion in 2025 and is growing at 12-15% annually. South Korea remains the global hub for aesthetic procedures — Korean clinics perform more procedures per capita than any country in the world. China’s medical aesthetics market is the largest by total value. Thailand and Vietnam are growing rapidly, driven by medical tourism and a rising middle class seeking non-surgical cosmetic procedures.
Mesotherapy specifically sits in a regulatory grey zone in several Asian markets. In some countries it is classified as a medical device (requiring full medical device registration), in others as a cosmetic product (simpler process), and in others as a pharmaceutical (most regulated). Your regulatory strategy must be country-specific.
South Korea: the most important market for aesthetic medicine
Korea’s MFDS (Ministry of Food and Drug Safety) regulates mesotherapy products as medical devices if they are injectable. Injectable hyaluronic acid, peptide solutions, and growth factor serums require Class II or Class III medical device registration — processes that take 12-24 months and require a Korean local agent with clinical documentation in Korean.
The distribution channel for Korean aesthetics: specialist aesthetic distributors who supply the country’s 30,000+ dermatology and plastic surgery clinics. These distributors attend the Korean Dermatological Association conference and the Korea Aesthetic Medicine Congress — the two primary events where new products are introduced to the buyer community. Personal relationships with clinic directors and dermatologists drive purchasing decisions more than advertising.
China: the scale opportunity with regulatory complexity
China’s NMPA (National Medical Products Administration) regulates injectable aesthetic products as Class III medical devices — the highest risk category. Registration takes 3-5 years for a new product and costs USD 200,000-500,000 in testing, clinical trial, and documentation. This is prohibitive for most Spanish SME mesotherapy brands entering China for the first time.
The practical China entry path for new aesthetic brands: topical (non-injectable) formulations registered as cosmetics (6-12 months process) for the professional clinic channel, plus partnership with Chinese distributors who handle parallel imports from South Korea (where registration may already exist) or Hong Kong. This is not the pure compliance path, but it is how many international aesthetic brands build initial China presence before committing to full NMPA registration.
Thailand and Vietnam: faster entry, growing market
Thailand’s FDA regulates injectable aesthetic products as medical devices under the Medical Device Act 2019. Registration takes 6-12 months for Class II devices — significantly faster than China or Korea. The Thai medical aesthetics market is driven by a combination of domestic consumers and medical tourists from the Middle East, Japan, and Southeast Asia.
Vietnamese aesthetic medicine is growing fast but regulatory enforcement is less consistent. Injectable products technically require registration but a significant portion of the clinic market in Ho Chi Minh City operates with products imported informally from Korea and Thailand. For a Spanish brand wanting formal distribution, a Vietnamese medical device importer with FDA Vietnam registration capability is the right partner.
What Asian distributors look for in a Spanish mesotherapy brand
Three things matter in the first conversation:
- CE certification — the European medical device certification is recognized as a quality benchmark across Asia’s aesthetic medicine market. Products with CE marking start the distributor conversation with credibility that non-CE products must spend significant time establishing through other documentation.
- Clinical studies — published or peer-reviewed clinical evidence of efficacy, preferably from independent European research institutions. Asian aesthetic medicine buyers — particularly Korean and Chinese clinic directors — are sophisticated researchers. They check PubMed.
- Training and education support — mesotherapy requires technique training. A Spanish brand that provides injector training workshops, protocol documentation, and ongoing clinical education creates practitioner loyalty that generic product distributors cannot replicate.
Working with a distribution partner that already has medical aesthetics channel relationships in multiple Asian markets is the most efficient path for a Spanish brand entering without existing Asia relationships. The regulatory complexity alone — different in every country — justifies working with a partner who has already navigated it.
Aesthetic Medicine Brand Entering Asia?
Asia Pro Distribution connects European medical aesthetics and cosmeceutical brands with qualified distributors across South Korea, China, Thailand, and Vietnam.
